- Home
- VOR vs DBVT Comparison
VOR vs DBVT Comparison
Compare VOR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- DBVT
- Stock Information
- Founded
- VOR 2015
- DBVT 2002
- Country
- VOR United States
- DBVT France
- Employees
- VOR N/A
- DBVT N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOR Health Care
- DBVT Health Care
- Exchange
- VOR Nasdaq
- DBVT Nasdaq
- Market Cap
- VOR 202.4M
- DBVT 250.5M
- IPO Year
- VOR 2021
- DBVT N/A
- Fundamental
- Price
- VOR $2.76
- DBVT $10.80
- Analyst Decision
- VOR Buy
- DBVT Buy
- Analyst Count
- VOR 7
- DBVT 4
- Target Price
- VOR $3.77
- DBVT $14.81
- AVG Volume (30 Days)
- VOR 46.8M
- DBVT 26.3K
- Earning Date
- VOR 08-07-2025
- DBVT 07-29-2025
- Dividend Yield
- VOR N/A
- DBVT N/A
- EPS Growth
- VOR N/A
- DBVT N/A
- EPS
- VOR N/A
- DBVT N/A
- Revenue
- VOR N/A
- DBVT $3,497,000.00
- Revenue This Year
- VOR N/A
- DBVT $1,700.53
- Revenue Next Year
- VOR N/A
- DBVT $535.67
- P/E Ratio
- VOR N/A
- DBVT N/A
- Revenue Growth
- VOR N/A
- DBVT N/A
- 52 Week Low
- VOR $0.13
- DBVT $2.21
- 52 Week High
- VOR $3.29
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- VOR 78.77
- DBVT 58.42
- Support Level
- VOR $2.25
- DBVT $10.53
- Resistance Level
- VOR $3.29
- DBVT $11.33
- Average True Range (ATR)
- VOR 0.52
- DBVT 0.76
- MACD
- VOR 0.18
- DBVT 0.14
- Stochastic Oscillator
- VOR 82.52
- DBVT 65.90
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.